Pierre Gholam, MD

Articles

Patient Profile 3: Second-Line Therapy for Advanced HCC

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

Frontline Therapy for Advanced HCC: Novel Combination Strategies

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

Role of Hepatitis Status in Selecting Therapy for HCC

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

Real-World Selection of Frontline Combination Therapy for Advanced HCC

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

Patient Profile 2: Frontline Therapy for Advanced HCC

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

Management of HCC: Advances in Biomarkers and Screening

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

Selection and Use of Systemic Therapy in Intermediate Stage HCC

July 13th 2022

Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

July 6th 2022

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

Early-Stage HCC: Role of Adjuvant Therapy

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

Patient Profile 1: Resection for Early/Intermediate Stage HCC

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

Patient Case: 63-Year-Old Woman With Advanced HCC

April 20th 2022

Drs Anthony B. El-Khoueiry, Daneng Li, Nicole Rich, and Pierre Gholam share treatment approaches for a 63-year-old woman who received an advanced HCC diagnosis with Child-Pugh A liver function.

How the Potential Use of Immunotherapy in Intermediate HCC Might Affect its Use in Advanced HCC

April 20th 2022

Dr Nicole Rich discusses immunotherapy and potential combinations in intermediate and advanced hepatocellular carcinoma.

Unmet Needs in the Treatment of Advanced HCC in Second-Line and Beyond

April 20th 2022

Key opinion leaders in gastrointestinal cancers provide insight on unmet needs and challenges in the treatment of advanced hepatocellular carcinoma in the second-line and beyond setting.

Sequencing Therapies After Frontline TKI Therapy in Advanced HCC

April 13th 2022

Experts in gastrointestinal cancers comment on their treatment approaches for patients with second-line advanced hepatocellular carcinoma who receive frontline TKI therapy.

Selecting the Appropriate Treatment in Second-Line and Beyond in Advanced HCC

April 13th 2022

Experts in gastrointestinal cancers share factors to consider when selecting the optimal second-line therapy for patients with advanced hepatocellular carcinoma.

Immunotherapies in Second-Line and Beyond in Advanced HCC

April 6th 2022

Pierre Gholam, MD, comments on systemic immunotherapy options for second-line and beyond treatment of advanced hepatocellular carcinoma.

Anti-Angiogenic Therapies in Second-Line and Beyond in Advanced HCC

April 6th 2022

Anthony B. El-Khoueiry, MD, reviews anti-angiogenic systemic therapy options for patients with advanced HCC in the second-line and beyond setting.